A
SUPN icon

Abingworth’s Supernus Pharmaceuticals SUPN Stock Holding History

Abingworth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,303,462
Closed -$27.8M – 17
2015
Q1 		$27.8M Sell
2,303,462
-575,866
-20% -$5.44M 11.83% 3
2014
Q4 		$23.9M Hold
2,879,328
– – 6.8% 5
2014
Q3 		$25M Sell
2,879,328
-720,672
-20% -$6.51M 14.96% 3
2014
Q2 		$39.3M Hold
3,600,000
– – 18.28% 2
2014
Q1 		$32.1M Hold
3,600,000
– – 17.74% 3
2013
Q4 		$27.1M Hold
3,600,000
– – 20.43% 3
2013
Q3 		$26.4M Hold
3,600,000
– – 15.02% 4
2013
Q2 		$23.2M Buy
+3,600,000
New +$21.2M 17.84% 3

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return

Abingworth's SUPN Position: Q2 2015 in Review

Abingworth sold out of Supernus Pharmaceuticals (SUPN) in Q2 2015, closing a stake of 2,303,462 shares — an estimated $27.8M sold.

Abingworth first reported a position in SUPN in Q2 2013 and held it in 8 quarters. The position peaked at $39.3M in Q2 2014. 166 funds tracked by Wall St. Rank hold SUPN as of Q2 2015.

  • Abingworth reported no remaining Supernus Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Abingworth sold 2,303,462 Supernus Pharmaceuticals shares in Q2 2015, an estimated $27.8M.
  • Abingworth first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Abingworth's Supernus Pharmaceuticals position peaked at $39.3M in Q2 2014.
  • 166 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2015.

Based on Abingworth's 13F filing for Q2 2015, filed 14 Aug 2015.